Investing.com - Financial Markets Worldwide

Edwards Lifesciences stock rises after SAPIEN 3 TAVR shows long-term benefits

Published 27/10/2025, 19:28
© Reuters.
EW
0.97%

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

The company announced seven-year data from the PARTNER 3 trial at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrating that its transcatheter aortic valve replacement (TAVR) technology maintains excellent long-term valve performance and durability. The data was published concurrently in The New England Journal of Medicine.

The seven-year analysis, which represents the most extensive clinical follow-up to date for low-risk TAVR and surgical aortic valve replacement (SAVR) patients, showed statistically comparable long-term valve performance between SAPIEN 3 TAVR and surgical alternatives. Valve durability indicators remained excellent and stable over time, with no significant difference in bioprosthetic valve failure (6.9% vs. 7.3%) or reintervention rates (6.0% vs. 6.7%).

"The PARTNER trials set out to determine whether TAVR could be a safe and effective, less invasive alternative to surgery," said PARTNER 3 co-principal investigator Martin Leon, M.D., professor of medicine at New York-Presbyterian Columbia University Irving Medical Center. "In the PARTNER 3 low risk trial, we again see the early clinical benefit of TAVR with SAPIEN 3 over surgery, as well as excellent long term valve performance and durability results for both therapies at seven years, which should be reassuring to patients and their physicians."

Edwards also highlighted 10-year follow-up data from the PARTNER 2 intermediate risk studies at the symposium, further reinforcing the company’s leadership in valve performance and patient outcomes across risk profiles.

Since its introduction more than two decades ago, the SAPIEN platform has been used to treat over 1 million patients worldwide.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.